{
  "id": "ic-h1",
  "version": "1",
  "drug": {
    "slug": "glp-1-agonists",
    "display": "GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)"
  },
  "supplement": {
    "slug": "oral-contraceptives",
    "display": "Oral contraceptives (combined pill)"
  },
  "severity": "moderate",
  "evidenceTier": "pk-study",
  "mechanism": "GLP-1 agonists slow gastric emptying, which can lower and delay the peak of pill hormones. For semaglutide the dedicated interaction study found bioequivalence held; for tirzepatide a single-dose study found hormone peaks roughly halved and the label added four-week barrier windows after each dose step. One class, two intensities.",
  "patientNotes": [
    "On tirzepatide (Mounjaro, Zepbound) with a pill: the label advises a non-oral method or backup contraception for four weeks after starting and after each dose increase.",
    "On injectable semaglutide (Ozempic, Wegovy) the dedicated study found no loss of pill exposure; a pharmacist conversation covers vomiting or diarrhea windows under your pill brand's missed-dose rules.",
    "Planning pregnancy: semaglutide is stopped at least two months ahead per the label."
  ],
  "pmids": [
    "25475122",
    "40330819",
    "42721915"
  ],
  "pubmedUrls": [
    "https://pubmed.ncbi.nlm.nih.gov/25475122/",
    "https://pubmed.ncbi.nlm.nih.gov/40330819/",
    "https://pubmed.ncbi.nlm.nih.gov/42721915/"
  ],
  "guideSlugs": [
    "semaglutide-birth-control"
  ],
  "guideUrls": [
    "https://supplementbrief.com/semaglutide-birth-control/"
  ],
  "pairUrl": "https://supplementbrief.com/interactions/glp-1-agonists/oral-contraceptives/",
  "reviewedBy": "natallia-kalistratava",
  "reviewerUrl": "https://supplementbrief.com/authors/natallia-kalistratava/",
  "lastVerified": "2026-09-19",
  "jsonUrl": "https://supplementbrief.com/data/v1/pairs/ic-h1.json",
  "htmlUrl": "https://supplementbrief.com/data/v1/pairs/ic-h1/"
}
